Novo Nordisk's stock price halved, dragging down its controlling shareholder and causing asset scale to shrink by one-third.

Golden Ten Data reported on March 12 that Novo Nordisk's performance decline last year caused its controlling shareholder's asset value to shrink by about one-third, weakening the shareholder's ability to invest in emerging biotechnology companies. The investment institution controlling Novo Nordisk, Novo Holdings, stated in a report released on Thursday that the assets it managed last year decreased to about 694 billion Danish kroner (10.8 billions USD). The pharmaceutical company, which produces the popular weight-loss drug Wegovy, is facing a sharp drop in sales this year because it is struggling to cope with lower-priced generic drugs and competition from its American rival, Eli Lilly. Due to the weight loss effect of the next-generation obesity injection drugs being less than expected, the company's stock price fell by about 48% last year and has dropped another 23% since early 2026. The pharmaceutical company's decision to halt stock buybacks, as well as the decline in the exchange rate of the US dollar against the Danish krone, also damaged Novo Holdings' investment returns. Market volatility has led the holding company to become more conservative in trading, adding only 12 new companies to its investment portfolio.